| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 31 Jan 2025 | 16 Jan 2025 |
| SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve financial results for the quarter and nine months ended December 31 2024 and interim dividend Intimation regarding record date for the purpose of interim dividend, if declared Board approved interim dividend for FY 2024-25 (As Per BSE Announcement Dated on 30/01/2025) | ||
| Board Meeting | 28 Oct 2024 | 9 Oct 2024 |
| SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve Financial Results for the quarter and half year ended September 30 2024 Financial results for quarter and half year ended September 30, 2024 (As Per BSE Announcement dated on 28.10.2024) | ||
| Board Meeting | 1 Aug 2024 | 15 Jul 2024 |
| SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2024 inter alia to consider and approve Quarterly Financial Results for Q1 of FY 2024-25. Outcome of Board Meeting (As per BSE Announcement Dated on 01/08/2024) | ||
| Board Meeting | 22 May 2024 | 13 May 2024 |
| SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2024. 2. Recommendation of final dividend if any on the equity shares of the Company for the financial year ended March 31 2024 for approval of the shareholders at the ensuing Annual General Meeting. Recommended Final Dividend of Rs. 5 per share Outcome of Board meeting (As Per BSE Announcement Dated on 22.05.2024) | ||
Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.
The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.
An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.
Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.
The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.
IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.
The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
